<i>BTN2A1-BRAF</i> fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: a case report.

Kong, Wei-Min; Guo, Yong-Jun; Ma, Jie; Shi, Chao

BTN2A1-BRAF fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: a case report.

Kong, Wei-Min; Guo, Yong-Jun; Ma, Jie; Shi, Chao.

Afiliação

Kong WM; Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Guo YJ; Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Ma J; Henan Key Laboratory of Molecular Pathology, Zhengzhou, China.
Shi C; Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Transl Cancer Res ; 12(1): 186-193, 2023 Jan 30.

Article em En | MEDLINE | ID: mdl-36760378

Palavras-chave

BRAF fusion; case report; epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI); non-small cell lung cancer (NSCLC); programmed cell death-ligand 1 (PD-L1)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article